2
Clinical Trials associated with ALX-0651 / CompletedNot Applicable A phase I, single-centre, randomised, single-blinded, placebo-controlled single ascending dose study, followed by an open-label extension, evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of ALX 0651, administered intravenously to healthy male volunteers. - ALX 0651 SAD and open-label extension in healthy male
A Phase I, Single-centre, Randomised, Single-blinded, Placebo-controlled Single Ascending Dose Study, Followed by an Open-label Extension, Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of ALX-0651, Administered Intravenously to Healthy Male Volunteers
The purpose of this first-in-man Phase I study is to determine whether the CXCR4-inhibitor ALX-0651 is safe and effective after single or multiple intravenous administrations to healthy male volunteers.
100 Clinical Results associated with ALX-0651
100 Translational Medicine associated with ALX-0651
100 Patents (Medical) associated with ALX-0651
100 Deals associated with ALX-0651